Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 4/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.86 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.86 |
| ▸ | NT5E | P21589 | 5/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972003 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL14700471 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL13957724 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL17022278 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL29564113 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL23440101 | 1.00 | DNPH1 (1.00) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL9607782 | 0.93 | P2RX3 (0.98) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL30076630 | 0.93 | P2RX3 (0.98) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL29941330 | 0.93 | P2RX3 (0.98) | DNPH1P2RX3P2RX2NT5EADORA3 | |
| SCHEMBL13033867 | 0.93 | P2RX3 (0.98) | DNPH1P2RX3P2RX2NT5EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | claimed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | claimed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | claimed |
| US-12201075-B2 | Methods and compositions for axillary shoot micropropagation of Cannabis and related plants | JUSHI IP, LLC (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230265444-A1 | GENE-EDITING IN CANNABIS PLANT | CANOPY GROWTH CORPORATION (CA) | 2023-08-24 | — | — | US | disclosed |
| EP-4228397-A1 | METHODS AND COMPOSITIONS FOR AXILLARY SHOOT MICROPROPAGATION OF CANNABIS AND RELATED PLANTS | Phytotech Labs, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3436601-B1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | CENTRE NAT RECH SCIENT (FR) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022081767-A1 | METHODS AND COMPOSITIONS FOR AXILLARY SHOOT MICROPROPAGATION OF CANNABIS AND RELATED PLANTS | PHYTOTECH LABS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220110278-A1 | METHODS AND COMPOSITIONS FOR AXILLARY SHOOT MICROPROPAGATION OF CANNABIS AND RELATED PLANTS | JUSHI IP, LLC | 2022-04-14 | — | — | US | disclosed |
| US-11209421-B2 | Cytidine deaminase expression level in cancer as a new therapeutic target | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-28 | — | — | US | disclosed |
| EP-2026810-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | Prendergast, Patrick T. (AU) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007131973-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | PRENDERGAST PATRICK T (AU) | 2007-11-22 | — | — | WO | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | DNPH1 1734/4885P2RX3 5/4885P2RX2 17/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | DNPH1 1734/4885P2RX3 5/4885P2RX2 17/4885 |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | DNPH1 3996/4885P2RX3 287/4885P2RX2 193/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | DNPH1 3917/4885P2RX3 247/4885P2RX2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.